1. Tianjin Neurological Institute, Tianjin Medical University General Hospital, Key Laboratory of Post-neurotrauma Neuro-repair and Regeneration in Central Nervous System, Ministry of Education, Tianjin City, Tianjin 300052, China. 2. Department of Dermatovenereology, Tianjin Medical University General Hospital, Tianjin 300052, China. 3. Tianjin Key Laboratory of Composite and Functional Materials, School of Materials Science and Engineering, Tianjin University, Tianjin, China. 4. College of Pharmacy, Kunming Medical University, Yunnan, China. * These authors contributed equally to this work.
Wu Y, Wang Y, Zhou J, Wang J, Zhan Q, Wang Q, Yang E, Jin W, Tong F, Zhao J, Hong B, Liu J, Kang C. Retraction of “Universal theranostic CRISPR/Cas13a RNA-editing system for glioma”. Theranostics 2024; 14(6):2489. doi:10.7150/thno.96658. https://www.thno.org/v14p2489.htm
Wu Y, Wang Y, Zhou J, Wang J, Zhan Q, Wang Q, Yang E, Jin W, Tong F, Zhao J, Hong B, Liu J, Kang C. Retraction of “Universal theranostic CRISPR/Cas13a RNA-editing system for glioma”. Theranostics 2024; 14(6):2489. doi:10.7150/thno.96658. https://www.thno.org/v14p2489.htm
CSE
Wu Y, Wang Y, Zhou J, Wang J, Zhan Q, Wang Q, Yang E, Jin W, Tong F, Zhao J, Hong B, Liu J, Kang C. 2024. Retraction of “Universal theranostic CRISPR/Cas13a RNA-editing system for glioma”. Theranostics. 14(6):2489.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.